Rami Komrokji, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, discusses the use of imetelstat for the treatment of myelodysplastic syndromes (MDS), which is currently under investigation in the Phase II IMerge trial (NCT02598661). In this study, imetelstat achieved prolonged transfusion independence (TI) in patients with lower-risk MDS who were non-del(5q) and lenalidomide/hypomethylating agent (HMA)-naïve. Imetelstat also demonstrated an encouraging safety profile and results suggest that this agent may have disease-modifying activity, providing a valuable therapeutic option for patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.